Concepedia

Kesang Li

KL

14

Publications

1K

Citations

13

H-Index

2013

Active since

Affiliations

Shanghai Cancer Institute(Current)

Renji Hospital

State Key Laboratory of Oncogene and Related Genes

University of Chinese Academy of Sciences

Eastern Hepatobiliary Surgery Hospital

Kesang Li is an author at Shanghai Cancer Institute specializing in medicine, tumor microenvironment, and cancer research.

ORCID

Top concepts

Publications per year

2013–2022

14

Publications

14

Development of T Cells Redirected to Glypican-3 for the Treatment of Hepatocellular Carcinoma

Huiping Gao, Kesang Li, Hong Tu et al. · Clinical Cancer Research · 2014 · 303 citations

Circular RNA circFGFR1 promotes progression and anti-PD-1 resistance by sponging miR-381-3p in non-small cell lung cancer cells

Pengfei Zhang, Xu Pei, Kesang Li et al. · Molecular Cancer · 2019 · 277 citations · Full text

Development of T cells carrying two complementary chimeric antigen receptors against glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinoma

Cheng Chen, Kesang Li, Hua Jiang et al. · Cancer Immunology Immunotherapy · 2016 · 107 citations · Full text

, , +8

SNHG22 overexpression indicates poor prognosis and induces chemotherapy resistance via the miR-2467/Gal-1 signaling pathway in epithelial ovarian carcinoma

Pengfei Zhang, Jing Wu, J. L. Luo et al. · Aging · 2019 · 52 citations · Full text

, , +16

The lipid platform increases the activity of STING agonists to synergize checkpoint blockade therapy against melanoma

Kesang Li, Yingyi Ye, Liqin Liu et al. · Biomaterials Science · 2020 · 46 citations

Rows per page

1–5 of 14